A study of migraine in systemic lupus erythematosus.

Isenberg, David; Meyrick-Thomas, Dianne; Snaith, M L; McKeran, R O; Royston, J. P.

doi:10.1136/ard.41.1.30

Cited by 55 publications

(43 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, Raynaud’s phenomenon has been shown to occur in patients with milder disease with frequent integument and musculoskeletal involvement 38 . On the other hand, Raynaud’s phenomenon has been inconsistently associated with migraine headaches in SLE patients 39,40 ; but we failed to demonstrate an association between headaches and NP-damage. Anemia was also associated with a longer time-to-NP damage; anemia is an indicator of disease activity and a predictor of overall damage accrual 41,42 .…”

Section: Discussioncontrasting

confidence: 88%

Time to neuropsychiatric damage occurrence in LUMINA (LXVI): a multi-ethnic lupus cohort

González

Pons-Estel

Zhang

et al. 2009

Lupus

View full text Add to dashboard Cite

The aims of this study were to examine the predictors of time-to-neuropsychiatric (NP) damage and its impact on mortality in 632 systemic lupus erythematosus (SLE) African American, Hispanic and Caucasian LUMINA patients, age ≥ 16 years and disease duration ≤ 5 years at baseline (T0). Time-to-NP damage and its impact on mortality were examined by Cox proportional hazards regressions. One-hundred eighty-five (29.3%) patients developed NP-damage over a mean (SD) disease duration of 5.6 (3.7) years. After adjusting for neuropsychiatric manifestations present, older age [Hazard ratio (HR)=1.02; 95% [Confidence interval (CI) 1.00–1.04)], Caucasian ethnicity (HR=1.87; 95% CI 1.22-2.87), disease activity over the disease course (HR=1.16; 95% CI 1.12–1.21), diabetes (HR=3.47; 95% CI 1.44–8.38) and abnormal illness-related behaviors (HR=1.05; 95% CI 1.02–1.08) were associated with a shorter time to NP-damage. Photosensitivity (HR=0.65; 95% CI 0.44–0.95), anemia (HR=0.56; 95% CI 0.31–0.98), Raynaud’s phenomenon (HR=0.49; 95% CI 0.34–0.72), a medium dose of prednisone (HR=0.56; 95% CI 0.35–0.92) and hydroxychloroquine use (HR=0.58; 95% CI 0.36–0.93) were associated with a longer time. NP-damage did not contribute to mortality. Older age, Caucasian ethnicity, disease activity and abnormal illness-related behaviors are associated with a shorter time-to-NP damage; hydroxychloroquine and a medium dose of prednisone with a longer time.

show abstract

Section: Discussioncontrasting

confidence: 88%

Time to neuropsychiatric damage occurrence in LUMINA (LXVI): a multi-ethnic lupus cohort

González

Pons-Estel

Zhang

et al. 2009

Lupus

View full text Add to dashboard Cite

show abstract

“…Headache is a common symptom in SLE patients (81)(82)(83), but whether there is a unique syndrome attributable to SLE is not clear. For pragmatic reasons the different types of headache that occur in SLE (84)(85)(86)(87)(88)(89) are incorporated in one case definition and include migraine and benign intracranial hypertension.…”

mentioning

confidence: 99%

The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes

Liang

Corzillius

Bae

et al. 1999

Arthritis & Rheumatism

1,812

193

View full text Add to dashboard Cite

Objective. To develop a standardized nomenclature system for the neuropsychiatric syndromes of systemic lupus erythematosus (NPSLE).Methods. An international, multidisciplinary committee representing rheumatology, neurology, psychiatry, neuropsychology, and hematology developed case definitions, reporting standards, and diagnostic testing recommendations. Before and after the meeting, clinician committee members assigned diagnoses to sets of vignettes randomly generated from a pool of 108 NPSLE patients. To assess whether the nomenclature system improved diagnostic agreement, a consensus index was developed and pre-and postmeeting scores were compared by t-tests.Results. Case definitions including diagnostic criteria, important exclusions, and methods of ascertainment were developed for 19 NPSLE syndromes. Recommendations for standard reporting requirements, minimum laboratory evaluation, and imaging techniques were formulated. A short neuropsychological test battery for the diagnosis of cognitive deficits was proposed. In the postmeeting exercise, a statistically significant improvement in diagnostic agreement was observed.Conclusion. The American College of Rheumatology (ACR) Nomenclature for NPSLE provides case definitions for 19 neuropsychiatric syndromes seen in SLE, with reporting standards and recommendations for laboratory and imaging tests. It is intended to facilitate and enhance clinical research, particularly multicenter studies, and reporting. In clinical settings, consultation with other specialists may be required. It should be useful for didactic purposes but should not be used uncritically or as a substitute for a clinical diagnosis. The complete case definitions are available on the ACR World Wide Web site: http://www.rheumatology .org/ar/ar.html.

show abstract

“…The adjusted odds ratio (OR) for lupus-related headache and Raynaud's syndrome was 1.7 (95% CI 1.1, 2.5). In addition, there was a strong independent relationship between headache and anti-beta2 glycoprotein I antibodies (adjusted OR 5.6 [95% CI 1.8,17.0]). The data from our chart review suggest that careful use of serotonin receptor agonists in patients with both Raynaud's syndrome and migraines may be undertaken, although caution would necessitate that these agents not be used in individuals with very severe Raynaud's (eg, digital ulcerations, and so on).…”

mentioning

confidence: 96%

Headache, Raynaud’s syndrome and serotonin receptor agonists in systemic lupus erythematosus

Bernatsky

Pineau

Lee³

et al. 2006

Lupus

View full text Add to dashboard Cite

There are potential concerns regarding serotonin receptor agonists in SLE patients with migraine, particularly patients with concomitant Raynaud's syndrome. We estimated the prevalence of lupus-related headache and Raynaud's syndrome in the Montreal General Hospital SLE clinic cohort and evaluated the relationship between these two variables in multivariable logistic regression models, controlling for age, sex, race, SLE duration and the presence of lupus anticoagulant and antibodies to cardiolipin and beta2 glycoprotein I. We also assessed, through chart review in those individuals with both Raynaud's syndrome and migraine, a history of serotonin receptor agonist use, and any associated worsening vasospasm. Based on Systemic Lupus Activity Measure (SLAM) scores, the cumulative incidence of lupus-related headache in our sample (n = 391) was 46.1%; the prevalence of Raynaud's syndrome was 49.4%. The adjusted odds ratio (OR) for lupus-related headache and Raynaud's syndrome was 1.7 (95% CI 1.1, 2.5). In addition, there was a strong independent relationship between headache and anti-beta2 glycoprotein I antibodies (adjusted OR 5.6 [95% CI 1.8, 17.0]). The data from our chart review suggest that careful use of serotonin receptor agonists in patients with both Raynaud's syndrome and migraines may be undertaken, although caution would necessitate that these agents not be used in individuals with very severe Raynaud's (eg, digital ulcerations, and so on).

show abstract

A study of migraine in systemic lupus erythematosus.

Cited by 55 publications

References 3 publications

Time to neuropsychiatric damage occurrence in LUMINA (LXVI): a multi-ethnic lupus cohort

Time to neuropsychiatric damage occurrence in LUMINA (LXVI): a multi-ethnic lupus cohort

The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes

Headache, Raynaud’s syndrome and serotonin receptor agonists in systemic lupus erythematosus

Contact Info

Product

Resources

About